Trial Profile
A Phase 1 Study of Intravenous EGFR-ErbituxEDVsMIT (EEDVsMit) in Children With Recurrent / Refractory Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor (EGFR) (ECREST Study)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 16 Feb 2022
Price :
$35
*
At a glance
- Drugs Mitoxantrone (Primary)
- Indications CNS cancer; Solid tumours
- Focus Adverse reactions
- Acronyms ECREST; ECREST study
- 30 Jan 2022 Status changed from recruiting to discontinued since study medication no longer in production.
- 20 Oct 2020 Planned End Date changed from 1 Apr 2021 to 1 Jul 2025.
- 20 Oct 2020 Planned primary completion date changed from 1 Feb 2021 to 1 Jul 2025.